Paul Diaz, Myriad Genetics president and CEO
A genetics testing outfit is bailing on its CRO services, choosing instead to refocus around precision drugs
In the past few months, there’s been a string of consolidation in the CRO space, with big players merging together and headline names in contract …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
